Table 2.
Results of meta-analysis and subgroup analysis on comorbidities in COVID-19 patients.
| Condition | Point estimate [95 % CI] | P value | Heterogeneity I2 (%) Q Ʈ2 |
||
|---|---|---|---|---|---|
| Non-survivors vs survivors | |||||
| Cardiovascular disease | 0.18 [0.1; 0.26] | <0.0001 | 70.0 | 26.41 | 0.010 |
| Cerebrovascular disease | 0.11 [0.04; 0.18] | 0.001 | – | 0.13 | – |
| Chronic kidney disease | 0.11 [0.04; 0.17] | 0.001 | 26.0 | 53.9 | – |
| Chronic liver disease | 0.01 [-0.07; 0.10] | 0.72 | – | 0.23 | – |
| COPD | 0.05 [-0.01; 0.11] | 0.10 | 52.0 | 8.37 | – |
| Diabetes | 0.14 [0.08; 0.19] | <00000.1 | 21.0 | 10.15 | – |
| Hypertension | 0.29 [0.23; 0.34] | <0.00001 | – | 6.78 | 0.010 |
| Malignancy | 0.04 [0.01; 0.06] | 0.008 | – | 1.91 | – |
| ICU vs non-ICU | |||||
| Cardiovascular disease | 0.14 [0.01; 0.27] | 0.004 | – | 0.01 | – |
| Chronic kidney disease | 0.04 [-0.02; 0.17] | 0.38 | – | – | – |
| COPD | 0.07 [-0.02; 0.17] | 0.12 | – | – | – |
| Diabetes | 0.01 [-0.33; 0.34] | 0.98 | 84.8 | 6.56 | 0.050 |
| Hypertension | 0.20 [-0.16; 0.56] | 0.28 | 83.1 | 5.92 | 0.060 |
| Malignancy | 0.05 [-0.06; 0.16] | 0.36 | – | – | – |
| Severe vs mild | |||||
| Cardiovascular disease | 0.10 [0.00; 0.20] | 0.05 | 90.4 | 62.74 | 0.015 |
| Cerebrovascular disease | 0.01 [-0.01; 0.03] | 0.32 | – | – | – |
| Chronic kidney disease | 0.01 [-0.01; 0.03] | 0.24 | – | – | – |
| Chronic liver disease | 0.03 [-0.02; 0.08] | 0.19 | – | 0.04 | – |
| COPD | 0.03 [0.00; 0.06] | 0.003 | – | 0.03 | – |
| Diabetes | 0.08 [0.02; 0.14] | 0.002 | 56.2 | 22.82 | 0.004 |
| Hypertension | 0.10 [0.08; 0.20] | 0.007 | 66.6 | 26.97 | 0.010 |
| Malignancy | 0.01 [0.00; 0.03] | 0.13 | – | 2.61 | – |
*COPD = chronic obstructive pulmonary disease.